logo

Arrowhead Pharmaceuticals Inc. (ARWR)



Trade ARWR now with
  Date
  Headline
1/7/2019 7:38:47 AM Arrowhead Begins Dosing In Phase 1 Study Of ARO-ANG3 For Treatment Of Dyslipidemias And Metabolic Diseases
1/7/2019 7:37:25 AM Arrowhead Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-APOC3 For Treatment Of Hypertriglyceridemia
10/31/2018 7:37:36 AM Arrowhead Reports Closing Of Agreements With Janssen
10/17/2018 7:18:43 AM William Blair Reiterates Arrowhead Pharmaceuticals Inc. (ARWR) At Outperform
10/15/2018 7:31:18 AM Arrowhead Files For Regulatory Clearance To Begin Phase 1 Study Of ARO-ANG3
10/4/2018 7:44:08 AM Arrowhead Enters $3.7 Bln License And Collaboration Agreements With Janssen
9/6/2018 7:31:46 AM Arrowhead Presents New ARO-HBV Clinical Data Showing HBsAg Reductions At World Gastroenterologists Summit
8/31/2018 7:30:55 AM Arrowhead Completes Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease
8/1/2018 7:41:05 AM Arrowhead Pharmaceuticals Earns $10 Mln Milestone Payment From Amgen
6/29/2018 7:34:41 AM Arrowhead Presents New Clinical Data On ARO-AAT At Alpha-1 National Education Conference
6/27/2018 7:34:04 AM Arrowhead Gets Positive EMA Opinion On Orphan Designation For ARO-AAT For Congenital Alpha-1 Antitrypsin Deficiency
6/18/2018 7:31:59 AM Arrowhead Completes Enrollment In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease